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Abstract
Genetic screening for HIV-related complications is emerging as a clinically relevant prediction tool.
A number of single nucleotide polymorphisms associated with conditions such as dyslipidemia and
type 2 diabetes have been identified in both the general population and in HIV-infected individuals.
Additionally, genome-wide association studies have looked at hepatitis C susceptibility in HIV-infected
people, and genetic studies are ongoing for coronary artery disease, osteoporosis, and neurocognitive
dysfunction. To date, understanding the contribution of genetic variation to the pathogenesis of
lipoatrophy and kidney disease in HIV-infection is limited.
Introduction and context
Diabetes,osteoporosis,chronicliverdisease,andcoronary
artery disease are just some of the common ‘metabolic’
these conditions tend to occur more frequently and at
an earlier age compared with the general population. One
theory is that the activation of the immune system and
subsequent inflammatory reactions to HIV infection
might cause premature aging [1], accelerating the onset
of these metabolic complications, despite the use of
effective antiretroviral therapy. Alternatively, antiretroviral
drugs themselves have been linked to metabolic compli-
cations, particularly the class of drugs called protease
inhibitors. However, these metabolic complications are at
least partly genetically determined; in fact, disease herit-
ability rates range from approximately 30 to 90%, depend-
ing on the condition. This highlights why it is important
to gain a deeper understanding of how genetic factors
contribute to metabolic complications in HIV-infected
people. Figure 1 summarizes genetic studies of common
metabolic complications in the general population and in
the setting of HIV-infection.
Recent advances
The genetic factors contributing to these major metabo-
lic disorders are typically complex and no single gene
mutation or variant is likely to explain a large proportion
of the differences in clinical presentation between
individuals. Rather, genome-wide association studies
(GWAS), which look for genetic variations associated
with a disease across the entire human genome in the
general population, have identified dozens of common
(i.e., present in at least 5% of the general population)
single nucleotide polymorphisms (SNPs) – single base
substitutions of one nucleotide for another – associated
with specific metabolic disorders. Identification of these
genetic differences may help to predict an individual’s
likelihoodofdevelopingadiseaseaswellastheirresponse
to treatment [2]. A catalogue of published GWAS is
available online [3].
In the case of type 2 diabetes, GWAS of the general
population have identified at least 22 SNPs associated
with the disease [4]. This is significant because insulin
resistance and type 2 diabetes are considered serious
complications in HIV-infected patients, given the
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conditions that affect millions of people, especially
later in life. Unfortunately, for those infected with HIV,
Published: 24 November 2010Figure 1. Current status of genetic studies of metabolic complications in HIV-infected individuals
Summary of the genome-wide association studies (GWAS) performed in the general population to discover genetic variations associated with various
metabolic disorders, including the number of single nucleotide polymorphisms (SNPs) identified and whether there have been genetic studies conducted in
HIV-infected individuals.
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importance of identifying these SNPs was confirmed very
recently in a long-term study of 644 white HIV-infected
patients [5]. In the study, 20% of the patients had an
unfavorable ‘genetic risk score’ (i.e., those patients who
carried multiple diabetes-associated SNPs), associated
with a threefold increase in the risk of developing
diabetes compared with patients who had a favorable
genetic score.For comparison,this increased riskis similar
to the effect of established risk factors such as advancing
age but greater than the effect of antiretroviral therapy.
Interestingly, the effect of the SNPs was still less than the
effect of having an increased body mass index.
The situation is similar for people affected by dyslipide-
mia, a condition where patients suffer from abnormal
levels of lipids (such as cholesterol and triglycerides) in
the blood, predisposing them to heart disease. All SNPs
consistently associated with serum lipid levels were
validated in a recent paper analyzing 745 HIV-infected
patients [6]. A patient’s genetic background and use of
antiretroviral therapy contributed to similar proportions
of lipid variation. A favorable genetic score (based on the
patient’s number of dyslipidemia-associated SNPs) was
associated with high levels of ‘bad’ cholesterol in 32% of
patients taking antiretroviral drugs; in patients with an
unfavorable genetic score, this figure rose to 53%.
Similarly, low levels of ‘good’ HDL cholesterol during
protease inhibitor-based antiretroviral therapy were seen
in 17% of patients with a favorable genetic score versus
42% with an unfavorable genetic score.
There are also some preliminary studies suggesting
that there is a genetic component to the mitochondrial
dysfunction widely implicated in lipoatrophy, a physi-
cally disfiguring condition that results in localized loss of
fat tissue and that has been linked to the use of certain
antiretroviral drugs in HIV-infected patients. Some
evidence for this comes from a recent report involving
536 white Multicenter AIDS Cohort Study participants,
which demonstrated that having one of a group of SNPs
in mitochondrial DNA (haplogroup H), is a risk factor
for lipoatrophy [7]. Additionally, a recent study of 103
Thai patients showed that the human leukocyte antigen
gene HLA-B*4001 was associated with lipotrophy,
implicating the immune system in this disorder [8].
However, these findings await confirmation in other
populations and, as yet, no unifying hypothesis of the
genetic predisposition to lipoatrophy has emerged.
Even less is understood about a direct genetic contribu-
tion to coronary artery disease risk in HIV-infected
individuals, but the international MAGNIFICENT con-
sortium is intending to report the results of a study on
this by Summer 2011. It features more than 600 HIV-
infected patients with coronary artery disease and more
than 1200 HIV-infected patients without this complica-
tion [9]. The SNPs evaluated in MAGNIFICENT will
include SNPs associated with coronary artery disease that
have already been identified in GWAS of the general
population. Recently, a step towards identifying a genetic
predisposition to cardiovascular problems in HIV-
infected persons was made through a small GWAS
(177 white male subjects genotyped) in which a SNP
involved in the development of atherosclerosis of the
carotid arteries was reported [10].
Chronic liver disease, often following infection with
hepatitis C virus, is another significant cause of death in
HIV-infected patients. Considerable enthusiasm was
generated by the description of variation in IL-28B (the
gene for interleukin 28B, which is responsible for the
production of the antiviral cytokine known as interferon-
l3) that accounts for a large proportion of the variation
in the spontaneous clearance of hepatitis C, as well as the
response to treatment with pegylated interferon and
ribavirin [12-15]. In addition, higher frequencies of the
sible for the lower response rate to hepatitis C treatment
genetic screening is already being advocated and is
becoming a key element in the stratification of patients
enrolled in clinical trials of new anti-hepatitis C
people infected with both HIV and hepatitis C [16], as
spontaneous hepatitis C viral clearance rates and
treatment response compared with patients carrying the
unfavorable form of the gene.
On a similar note, a genetic analysis of osteoporosis risk
in HIV-infected individuals is overdue, given the aging
HIV-infected population, the remarkably increased rates
of this complication in the setting of HIV-infection, and
the large degree of heritability of osteoporosis (estimated
at 60-90%). Several GWAS in the general population
(reviewed in [11]) have identified around 30 osteoporosis-
associated SNPs.
Unfortunately, there are also several chronic complica-
tionsofHIVinfectionwheretherearenoclearinsightsinto
the genetics involved in pathogenesis, such as kidney
disease and HIV-associated neurocognitive disorders,
although a GWAS to evaluate a potential genetic predis-
position in the latter is ongoing. In addition, no new
reports have been published since the identification of a
possible genetic association of a SNP in resistin (a gene
previously implicated in obesity and insulin resistance)
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IL-28B unfavorable gene variants appear to be respon-
IL-28B seen in individuals of African or Hispanic origin.
IL-28B compounds. plays a similarly important role in
having the favorable gene variants improved IL-28Bwith certain features of the metabolic syndrome in a study
of 135 candidate genes in 189 genotyped participants on
antiretroviral therapy in 2008 [17].
Implications for clinical practice
Despite the current gaps in our knowledge, genetic
screening for HIV-related metabolic complications is
emerging as a clinically relevant prediction tool. In fact,
genetic prediction is already used in routine HIV care to
identify individuals at risk of developing a hypersensi-
tivity reaction to the antiretroviral drug abacavir [18].
However, the nearly 100% accuracy of this test is because
only a single locus (HLA*B5701) is involved. This is in
distinct contrast to the multiple SNPs implicated in
common metabolic disorders. Thus, the best guess based
on current knowledge is that a panel of SNPs will need to
be screened to produce a ‘risk score’ for metabolic
complications in HIV-infected individuals, and that this
will need to be combined with clinical variables to give
an accurate prediction.
An additional, consistent lesson learned from GWAS is
that the known common SNPs for a disorder account for
less than 10% of the variability in disease seen between
individuals. This applies to all metabolic and non-
metabolic disorders assessed in GWAS [2,19]. In the next
few years, the genetic basis of an increased fraction of the
variability between individuals is likely to be uncovered.
This will be achieved by re-sequencing the risk genes
documented in GWAS (in order to identify rare variants
causally implicated in the phenotype), large scale
genome sequencing projects (see [20]) and whole
genome sequencing of people with extreme versions of
the disorders. However, all these approaches are costly
[21]. Costs per patient are, as of June 2010, 400 US
dollars (USD) for a single GWAS and around 10,000
USD for whole genome sequencing. Until these tests
become cheaper, re-assessing the SNPs associated with
metabolic disorders in the general population and
screening HIV-infected patients for them (at a cost of
0.5-1 USD per SNP, per patient) remains a reasonable
approach.
Abbreviations
GWAS, genome wide association study; SNP, single
nucleotide polymorphism; USD, US dollars.
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